UCT presented their innovative application of CA-62 Biomarker technology to the leaders in cancer healthcare and detection in attendance at this important global event held in Nur-Sultan, Kazakhstan. UCT’s presentation was well received as it provided details about how their new CA-63 Biomarker Cancer Test works to detect the presence of a variety of epithelial cancers through a routine blood sample. The presentation also summarized the results from the numerous studies conducted on over 5,000 human blood samples, demonstrating results with sensitivity of greater than 90% and specificity of 95%.
UCT’s unique cancer testing technology may prove to be a significant advancement in the ability of oncologists around the globe to successfully detect the presence of cancer at the earliest stages of the disease as well as monitor the effectiveness of ongoing cancer treatments or detecting the return of cancer for those in remission.
“The World Cancer Leader Summit represents a great opportunity to raise awareness and share the benefits of our CA-62 Biomarker Cancer Test with leaders in the space”, said UCT co-founder and CEO, Viatcheslav Kondratiev. “UCT found the meeting to be very productive in educating experts and driving interest in the company.”
The meeting afforded an exceptional opportunity for UCT to meet directly with leaders in cancer detection and treatment space. UCT also spent their time networking to raise awareness of UCT’s unique technology offering that can help save the lives of cancer patients everywhere through early detection.
Contact:
Viatcheslav Kondratiev, CEO
Universal Cancer Technologies (UCT)
800 Petrolia Road, Unit 3,
Toronto, ON M3J 3K4 Canada
Phone: 416-661-7890
Email: [email protected]
About UCT
UCT is an emerging biotechnology company that has developed a sensitive cancer test that can reliably measure the amount of N-glycoprotein CA-62 biomarker in a routine blood draw. The test can detect the majority of epithelial cancer types at all stages of the disease (Stage I through Stage IV), even before a patient may become symptomatic. Because of its non-invasive approach and rapid turnaround time UCT’s CA-62 biomarker test is ideal for screening as well as for monitoring the success of ongoing cancer treatments and identifying relapses in remission patients.
-30-